$NAMS 8-K SEC Filings

Filed On	Filing
29 Sep 2026	8-K: Other Events NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
21 Sep 2026	8-K: Other Events On September 21, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) along with its partner Menarini Group (“Menarini”) announced that the European Commission (“EC”) has granted marketing authorization for Ubeslo® (obicetrapib 10 mg m...
14 Aug 2026	8-K: Departure/Election of Directors or Officers; Compensation
05 Aug 2026	8-K: Results of Operations and Financial Condition
24 Jul 2026	8-K: Other Events
22 Jul 2026	8-K: Departure/Election of Directors or Officers; Compensation
03 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
07 May 2026	8-K: Results of Operations and Financial Condition
24 Apr 2026	8-K: Departure/Election of Directors or Officers; Compensation
02 Mar 2026	8-K: Regulation FD Disclosure
18 Feb 2026	8-K: Results of Operations and Financial Condition
09 Jan 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
05 Nov 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
02 Sep 2025	8-K: Regulation FD Disclosure
18 Aug 2025	8-K: Regulation FD Disclosure; Other Events
15 Aug 2025	8-K: Entry into a Material Definitive Agreement
06 Aug 2025	8-K: Results of Operations and Financial Condition
30 Jul 2025	8-K: Regulation FD Disclosure; Other Events
11 Jul 2025	8-K: Departure/Election of Directors or Officers; Compensation
11 Jun 2025	8-K: Regulation FD Disclosure

Comments